Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

EGFR Gene Mutations Is it Prognostic or Predictive in Surgically Resected Lung Cancer?

EGFR Gene Mutations Is it Prognostic or Predictive in Surgically Resected Lung Cancer? EDITORIAL EGFR Gene Mutations Is it Prognostic or Predictive in Surgically Resected Lung Cancer? Tetsuya Mitsudomi, MD,* and Hirohito Tada, MD† he role of mutation of the EGFR gene as a predictive factor for epidermal growth factor Ttyrosine kinase inhibitor (EGFR-TKI) therapy in the treatment of metastatic non–small- cell lung cancer (NSCLC) was established by the IPASS trial, which compared gefitinib with platinum doublet chemotherapy in clinically selected patients with a higher chance of EGFR mutation. In that trial, the hazard ratio (HR) of progression-free survival for gefitinib was 0.48 in patients with EGFR mutation, whereas it was 2.85 for patients without EGFR mutation. The superiority of EGFR-TKI over chemotherapy, in terms of progression-free survival, was confirmed in five subsequent phase III trials in patients selected on the basis 2–6 of EGFR gene mutation. However, the role of EGFR mutation as a predictive or prog- nostic factor remains unclear in patients with earlier-stage disease, who undergo surgical resection. In 2008, Marks et al. reported a more favorable prognosis for NSCLC patients with EGFR mutation, compared with those without mutation, as assessed using univariate analy- sis. After this report, we published the similar observation that EGFR mutation was prog- nostic in univariate http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

EGFR Gene Mutations Is it Prognostic or Predictive in Surgically Resected Lung Cancer?

Tada, Hirohito
Journal of Thoracic Oncology , Volume 7 (12) – Dec 1, 2012
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/egfr-gene-mutations-is-it-prognostic-or-predictive-in-surgically-tbdl0hS7jP

References (16)

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e3182743a0c
pmid
23154542
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL EGFR Gene Mutations Is it Prognostic or Predictive in Surgically Resected Lung Cancer? Tetsuya Mitsudomi, MD,* and Hirohito Tada, MD† he role of mutation of the EGFR gene as a predictive factor for epidermal growth factor Ttyrosine kinase inhibitor (EGFR-TKI) therapy in the treatment of metastatic non–small- cell lung cancer (NSCLC) was established by the IPASS trial, which compared gefitinib with platinum doublet chemotherapy in clinically selected patients with a higher chance of EGFR mutation. In that trial, the hazard ratio (HR) of progression-free survival for gefitinib was 0.48 in patients with EGFR mutation, whereas it was 2.85 for patients without EGFR mutation. The superiority of EGFR-TKI over chemotherapy, in terms of progression-free survival, was confirmed in five subsequent phase III trials in patients selected on the basis 2–6 of EGFR gene mutation. However, the role of EGFR mutation as a predictive or prog- nostic factor remains unclear in patients with earlier-stage disease, who undergo surgical resection. In 2008, Marks et al. reported a more favorable prognosis for NSCLC patients with EGFR mutation, compared with those without mutation, as assessed using univariate analy- sis. After this report, we published the similar observation that EGFR mutation was prog- nostic in univariate

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Dec 1, 2012

There are no references for this article.